Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer 英文论文文献.docVIP

Breast Cancer Research Vol 5 No 2 Arteaga Commentary Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer Carlos L Arteaga Departments of Medicine and Cancer Biology, Vanderbilt University School of Medicine; and Breast Cancer Research Program, Vanderbilt-Ingram Comprehensive Cancer Center, Nashville, Tennessee, USA Corresponding author: Carlos L Arteaga (e-mail: carlos.arteaga@) Received: 18 October 2002 Revisions received: 2 January 2003 Accepted: 16 January 2002 Published: 3 February 2003 Breast Cancer Res 2003, 5:96-100